Price of NovoSeven injection angers hemophilia patients

Published: 2009-06-11 07:00:00

Updated: 2009-06-11 07:00:00

The final health insurance price for NovoSeven (recombinant activated clotting factor VII ~ rFVIIa) injection 240 KIU (4.8 mg) will be finally decided by the Ministry for Health, Welfare and Family Affair committee, since Novo Nordisk, the maker of the drug, is calling for a more “profitable'' pr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK